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Intensive glucose control after the onset
of type 1 diabetes has been suggested
to preserve C-peptide production (1–3).
In people with type 1 diabetes, sensor-
augmented pump (SAP) use improved
glycemic control, particularly when
used .6 days/week (4). As previously
reported, subjects with type 1 diabetes
were randomized to either 3 days of
in-hospital hybrid closed-loop therapy
followed by SAP therapy or usual care
(5). In the primary intent-to-treat anal-
ysis, no significant differences existed in
HbA1c or C-peptide between the two
groups at 1 year. In our post hoc analy-
sis, we hypothesized that more frequent
sensor use in the SAP group would be
associated with lower HbA1c levels and
preservation of C-peptide production at
1 year.
Subjects in the SAP group (n 5 46)
were stratified by median SAP use of
12.4 h/day. HbA1c and C-peptide levels
were compared at baseline and 3, 6, 9,
12, and 24 months. At 12 months of
follow-up, the median HbA1c values
for those with SAP use above versus
below the median were lower (7.0%
[Q1, Q3 6.0, 7.5] vs. 7.7% [7.1, 8.5],
P 5 0.007).
All three C-peptide measures were
50–79% higher at 12 months in the
above versus below median SAP use
group. However, these nonsignificant
trends were no longer present at 24
months. No statistically significant differ-
ences were seen in fasting, peak, or area
under the curve C-peptide levels between
the two groups at any time period over
2 years of follow-up. All three C-peptide
measures declined .50% from 12 to
24 months in the high SAP use group,
although HbA1c levels remained similar
(Fig. 1).
As HbA1c levels remained similar at 12
and 24 months in the above median SAP
use group, it can be concluded that fac-
tors other than glycemic control were
likely related to the .50% reduction
in C-peptide production during the sec-
ond year after diagnosis. In subjects hav-
ing type 1 diabetes for .1 year, only
consistent ($6 days/week) use of a SAP
system was shown to improve glycemic
control (2). In our analysis, we stratified
subjects by the frequency of use of SAP
over the year of follow-up (the primary
end point), and median use (12.4 h) was
about half the day. This frequency of SAP
use may not have been sufficient to
reduce HbA1c levels adequately to pre-
serve b-cell function. The drop-off in fre-
quency of continuous glucose monitor
use in this and previous studies may
be due to less sophisticated earlier-
generation continuous glucose monitor
technologies, such as the Medtronic
Sof-sensor used in the initial study (5).
Further studies with larger numbers of
subjects who are followed for a longer
time period and are using improved
technology will be important to further
evaluate this hypothesis in the future.
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Figure 1—Comparison over 2 years of those who used the SAP above the median comparedwith
those who used the SAP below the median use in the first 12 months. A: HbA1c levels (%).
B: Fasting C-peptide (nmol/L). C: Peak C-peptide (nmol/L). D: Area under the curve (AUC)
C-peptide (nmol min/L). *P , 0.05 at 9 months and P , 0.01 at 12 and 24 months.
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